Skin discolorations and skin lesions due to vascular pathologies are common clinical features in systemic lupus erythematosus. A variety of clinical manifestations such as Raynaud’s phenomenon, acrocyanosis, livedo patterns, erythematous or violaceous macules and papules or necrosis are triggered by heterogeneous pathophysiological mechanisms such as vasospasm, vasculitis or thromboembolism. A standardized macro- and microvascular assessment is necessary to establish the correct diagnosis. We describe and illustrate common clinical features of vascular skin manifestations in systemic lupus erythematosus and present a diagnostic algorithm. Lupus (2010) 19, 1087—1095.
Carpentier PH[Definition and epidemiology of vascular acrosyndromes] . Rev Prat1998; 48: 1641-1646.
2.
Gayraud M.Raynaud’s phenomenon. Joint Bone Spine2007; 74: e1-8.
3.
Jennette JC, Falk RJ, Andrassy K., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum1994 ; 37: 187-192.
Ward MM, Poilisson RPA meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus. Arthritis Rheum1989; 32: 1226-1232.
9.
Cervera R., Khamashta MA, Font J., et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore)1993; 72: 113-124.
10.
Constallat LTL , Coimbra VAM.Systemic lupus erythematodes: clinical and laboratory aspects related to age at disease onset. Clin Experim Rheum1994; 12: 603-607.
Spencer-Green G.Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of a transition to secondary disease. Arch Int Med1998; 158: 596-600.
13.
Hashimoto H. , Tsuda H., Hirano T., Takasaki Y., Matsumoto T., Hirose S.Differences in clinical and immunological findings of systemic lupus erythematosus related to age. J Rheumatol1987; 14: 497-501.
14.
Furtado RN, Pucinelli ML, Cristo VV, Andrade LE, Sato EIScleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud’s phenomenon in SLE patients . Lupus2002; 11: 35-41.
15.
Rodriguez VE , Gonzalez-Pares EN, Rivera C.Clinical manifestations and vascular events in patients with lupus erythematosus anticardiolipin antibodies and Raynaud’s phenomenon. P R Health Sci J2006; 25: 307-313.
16.
Stratta P., Canavese C., Ciccone G., et al. Correlation between cytomegalovirus infection and Raynaud’s phenomenon in lupus nephritis. Nephron1999 ; 82: 145-154.
17.
Dimant J., Ginzler E., Schlesinger M., et al. The clinical significance of Raynaud’s phenomenon in systemic lupus erythematosus. Arthritis Rheum1979; 22: 815-819.
18.
Lefford F., Edwards JCNailfold capillary microscopy in connective tissue disease: a quantitative morphological analysis. Ann Rheum Dis1986 ; 45: 741-749.
19.
Choojitarom K., Verasertniyom O., Totemchokchyakarn K., Nantiruj K., Sumethkul V., Janwityanujit S.Lupus nephritis and Raynaud’s phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. Clin Rheumatol2008; 27: 345-351.
20.
Naldi L., Locati F., Marchesi L., et al. Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: a case-control study. Ann Rheum Dis1993; 52: 219-222.
21.
Bongard O., Bounameaux H., Miescher PA, De Moerloose P.Association of anticardiolipin antibodies and abnormal nailfold capillaroscopy in patients with systemic lupus erythematosus. Lupus1995; 4: 142-144.
22.
Merkel PA, Chang Y., Pierangeli SS, Convery K., Harris EN, Polisson RPThe prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med1996; 101: 576-583.
23.
Vayssairat M., Abuaf N., Baudot N., Deschamps A., Gaitz JPAbnormal IgG cardiolipin antibody titers in patients with Raynaud’s phenomenon and/or related disorders: prevalence and clinical significance. J Am Acad Dermatol1998; 38: 555-558.
24.
Caccavo D., Del Porto F., Garzia P., et al. Raynaud’s phenomenon and antiphospholipid antibodies in systemic lupus erythematosus: is there an association?Ann Rheum Dis2003; 62: 1003-1005.
25.
Merlen JFAcrocyanosis: certain paradoxes, its pathogenesis. Phlebologie1982; 35: 731-737.
26.
Planchon B. , Becker F., Carpentier PH, et al. [Acrocyanosis: changing concepts and nosological limitations]. J Mal Vasc2001; 26: 5-15.
27.
Ramos-Casals M., Nardi N., Lagrutta M., et al. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore)2006 ; 85: 95-104.
28.
Tshering D. , Amdo MD, James A., Welker DOAn approach to the diagnosis and treatment of cryofibrinogenemia. Am J Med2004; 116: 332-337.
29.
Vitali C., Bencivelli W., Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol1992; 10: 541-547.
30.
Vlachoyiannopoulos PG, Karassa FB, Karakostas KX, Drosos AA, Moutsopoulos HMSystemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus1993; 2: 303-312.
31.
Drenkard C. , Villa AR, Reyes E., Abello M., Alarcon-Segovia D.Vasculitis in systemic lupus erythematosus. Lupus1997 ; 6: 235-242.
32.
Alarcon-Segovia D.Clinical manifestations of the antiphospholipid syndrome. J Rheumatol1992; 19: 1778-1781.
33.
Goldberger E., Elder RC, Schwartz RA, Phillips PEVasculitis in the antiphospholipid syndrome. A cause of ischemia responding to corticosteroids . Arthritis Rheum1992; 35: 569-572.
34.
Toussirot E. , Figarella-Branger D., Disdier P., Harle JR, Weiller PJAssociation of cerebral vasculitis with a lupus anticoagulant. A case with brain pathology . Clin Rheumatol1994; 13: 624-627.
Diogenes MJ , Diogenes PC, de Morais, Carneiro RM, Neto CC, Duarte FB, Holanda RRCutaneous manifestations associated with antiphospholipid antibodies. Int J Dermatol2004; 43: 632-637.
37.
Weinstein S. , Piette W.Cutaneous manifestations of antiphospholipid antibody syndrome. Hematol Oncol Clin North Am2008; 22: 67-77.
38.
Merrill JTAntibodies and clinical features of the antiphospholipid syndrome as criteria for systemic lupus erythematosus. Lupus2004 ; 13: 869-876.
39.
Duran S., Gonzalez LA, Alarcon GSDamage, accelerated atherosclerosis, and mortality in patients with systemic lupus erythematosus: lessons from LUMINA, a multiethnic US cohort . J Clin Rheumatol2007; 13: 350-353.
40.
Brown GE, O’Leary PASkin capillaries in scleroderma. Arch Intern Med1925; 36: 73-88.
41.
Schmidt JA, Caspary I., von Bierbrauer A., et al. Standardisierung der Nagelfalz-Kapillarmikroskopie in der Routinediagnostik . VASA1997; 26: 5-10.
42.
Sander O., Sunderkötter C., Kötter I., et al. Kapillarmikroskopie: Durchführung und Nomenklatur. Z Rheumatol2010; 69: 253-262.
43.
Carpentier P.Atlas der Kapillarmikroskopie. Abbott GmbH Wiesbaden; 1983.
Harper FE, Maricq HR, Turner RE, Lidman RW, Leroy ECA prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report. Am J Med1982 ; 72: 883-888.
46.
Carpentier PH , Maricq HRMicrovasculature in systemic sclerosis . Rheum Dis Clin North Am1990; 16: 75-91.
47.
Mannarino E. , Pasqualini L., Fedeli F., Scricciolo V., Innocente S.Nailfold capillaroscopy in the screening and diagnosis of Raynaud’s phenomenon. Angiology1994; 45: 37-42.
48.
Nagy Z., Czirjak L.Nailfold digital capillaroscopy in 447 patients with connective tissue disease and Raynaud’s disease. J Eur Acad Dermatol Venereol2004; 18: 62-68.
49.
Pavlov-Dolijanovic S., Damjanov N., Ostojic P., et al. The prognostic value of nailfold capillary changes for the development of connective tissue disease in children and adolescents with primary Raynaud phenomenon: A follow-up study of 250 patients. Pediatr Dermatol2006; 23: 437-442.
50.
Meli M., Gitzelmann G., Koppensteiner R., Amann-Vesti BRPredictive value of nailfold capillaroscopy in patients with Raynaud’s phenomenon. Clin Rheumatol2006; 25: 153-158.
51.
Cutolo M., Matucci Cerinic M.Nailfold capillaroscopy and classification criteria for systemic sclerosis . Clin Exp Rheumatol2007; 25: 663-665.
52.
Cutolo M., Sulli A., Secchi ME, Pizzorni C.[Capillaroscopy and rheumatic diseases: state of the art]. Z Rheumatol2006; 65: 290-296.
53.
Ingegnoli F. , Zeni S., Meani L., Soldi A., Lurati A., Fantini F.Evaluation of nailfold videocapillaroscopic abnormalities in patients with systemic lupus erythematosus. J Clin Rheumatol2005; 11: 295-298.
54.
Riccieri V. , Spadaro A., Ceccarelli F., Scrivo R., Germano V., Valesini G.Nailfold capillaroscopy changes in systemic lupus erythematosus: correlations with disease activity and autoantibody profile . Lupus2005; 14: 521-525.
55.
Maricq HR, LeRoy EC, D’Angelo WA, et al. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum1980 ; 23: 183-189.
56.
Cutolo M., Sulli A., Secchi ME, Paolino S., Pizzorni C.Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases A future tool for the analysis of microvascular heart involvement? . Rheumatology (Oxford)2006; 45(Suppl 4): iv43-46.
57.
Sander O., Iking-Konert C., Ostendorf B., Schneider M.Capillaroscopy in systemic lupus erythematosus. Ann Rheum Dis2008; 67(Suppl II): 567.
58.
Maricq HR, Harper FE, Khan MM, Tan EM, LeRoy ECMicrovascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease. Clin Exp Rheumatol1983; 1: 195-205.
59.
Kabassakal V., Elvins DM, Ring EFJ, McHugh NJQuantitative nailfold capillaroscopy findings in a population with connective tissue disease and healthy controls. Ann Rheum Dis1996; 55: 507-512.
60.
Furtado RN, Pucinelli ML, Cristo VV, Andrade LE, Sato EIScleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud’s phenomenon in SLE patients . Lupus2002; 11: 35-41.
61.
Redisch W., Messina EJ, Hughes G., McEwen C.Capillaroscopic observations in rheumatic diseases. Ann Rheum Dis1970; 29: 244-253.
62.
Granier F., Vayssairat M., Priollet P., Housset E.Nailfold capillary microscopy in mixed connective tissue disease. Arthritis Rheum1986; 29: 189-195.
63.
Kuryliszyn-Moskal A., Klimiuk PA, Sierakowski S., Ciołkiewicz M.Vascular endothelial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities. Arch Immunol Ther Exp2007 ; 55: 179-185.
64.
Bongard O., Miescher PA, Bournameaux H.Altered skin microcirculation in patients with systemic lupus erythematosus . Int J Microcirc1997; 17: 184-189.
65.
Caspary L., Schmees C., Schoetensack I., et al. Alterations of the nailfold capillary morphology associated with Raynaud phenomenon in patients with systemic lupus erythematosus. J Rheumatol1991; 18: 559-566.
66.
Dancour MA, Vaz JL, Bottino DA, Bouskela E.Nailfold videocapillaroscopy in patients with systemic lupus erythematosus . Rheumatol Int2006; 26: 633-637.
67.
Bongard O., Bournameaux H., Mischer PAde Moerloose P.Association of anticardiolipin antibodies and abnormal nailfold capillaroscopy in patients with systemic lupus erythematosus. Lupus1995; 4: 142-144.
68.
Sulli A., Pizzorni C., Cutolo M.Nailfold videocapillaroscopy abnormalities in patients with antiphospholipid antibodies. J Rheumatol2000; 27: 1574-1576.
